Lucy Common: key facts
- Kind of voice
- Clinician
- Role
- clinical nursing advisor at NICE
- Quoted on
- Cancer, Children's health
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
- First quoted
- 10 Sept 2026
“For women living with platinum-resistant ovarian cancer, the impact of repeated chemotherapy cycles goes far beyond the clinic. We heard from patients who had given up work, stopped seeing friends, and were relying on family and carers just to get through each day. Mirvetuximab soravtansine offers not just longer survival, but a meaningfully different treatment experience, with fewer hospital visits and a side effect profile that allows women to maintain more of their normal life.”
What Lucy Common has said
“Having time before the onset of stage 3 diabetes is not just a clinical benefit; it can make a meaningful difference to people's lives, their mental wellbeing, and the wellbeing of the families and carers who support them.”
clinical nursing advisor at NICE · Children's health · 10 Sept 2026 · Immunotherapy to delay type 1 diabetes onset approved by NICE ↗
Where Lucy Common has been quoted
- Treatment for chemotherapy-resistant ovarian cancer approved for NHS usepharmaceutical-journal.com · 30 Sept 2026
- Immunotherapy to delay type 1 diabetes onset approved by NICEpulsetoday.co.uk · 10 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Doctors, nurses, allied health professionals and other registered clinicians quoted in a clinical capacity. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.